Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors

International Journal of Clinical Oncology

Volumn 15, Issue 6, 2010, Pages 588-593

  Heudel, Pierre ^b   Cimarelli, Sebastien ^a   Montella, Anthony ^a   Bouteille, Catherine ^a   Mognetti, Thomas ^a  

^a CENTRE LÉON BÉRARD   (France)

^b NONE

Author keywords

Breast cancer; Monitoring therapy; PET FDG; Triple negative breast cancer

Indexed keywords

ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DRUG TUMOR LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; METASTASIS; NON INVASIVE MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 78651103585     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-010-0120-3     Document Type: Article

References (25)

1. American Cancer Society (2007) Cancer facts and figures. Atlanta, GA. http://www.cancer.org/downloads/STT/Global-cancer-facts-and-figures-2007-rev. pdf. Accessed 28 October 2009
2. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
3. RL Wahl BA Siegel RE Coleman, et al. 2004 Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group J Clin Oncol 22 277 285 14722036 10.1200/JCO.2004.04.148 (Pubitemid 41095092)
4. U Veronesi C De Cicco VE Galimberti, et al. 2007 A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases Ann Oncol 18 473 478 1:STN:280:DC%2BD2szlt1ajtg%3D%3D 17164229 10.1093/annonc/mdl425 (Pubitemid 46359625)
5. TA Heusner S Kuemmel S Hahn, et al. 2009 Diagnostic value of full-dose FDG-PET/CT for axillary lymph node staging in breast cancer patients Eur J Nucl Med Mol Imaging 36 1543 1550 1:CAS:528:DC%2BD1MXht1WhtL3O 19415270 10.1007/s00259-009-1145-6
6. N Avril CA Rose M Schelling, et al. 2000 Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations J Clin Oncol 18 3495 3502 1:STN:280:DC%2BD3M%2Fhsl2hsA%3D%3D 11032590
7. J Dose Schwarz M Bader L Jenicke, et al. 2005 Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET J Nucl Med 467 1144 1150
8. N Avril M Schelling J Dose, et al. 1999 Utility of PET in breast cancer Clin Positron Imaging 2 261 271 14516650 10.1016/S1095-0397(99)00032-1
9. RP Baum C Przetak 2001 Evaluation of therapy response in breast and ovarian cancer patients by positron emission tomography (PET) Q J Nucl Med 45 257 268 1:STN:280:DC%2BD387mtVaitA%3D%3D 11788818
10. F Wilcoxon 1945 Individual comparisons by ranking methods Biometrics Bull 1 80 83 10.2307/3001968
11. WH Kruskal WA Wallis 1952 Use of ranks in one-criterion variance analysis J Am Stat Assoc 47 583 621 10.2307/2280779
12. SE Singletary C Allred P Ashley, et al. 2002 Revision of the American joint Committee on cancer staging system for breast cancer J Clin Oncol 20 3628 3636 12202663 10.1200/JCO.2002.02.026 (Pubitemid 34983222)
13. 18F]-d-glucose Cancer 82 2227 2234 1:STN:280: DyaK1c3nt1agtg%3D%3D 9610703 10.1002/(SICI)1097-0142(19980601)82:11<2227:: AID-CNCR18>3.0.CO;2-W (Pubitemid 28240830)
14. N Avril M Menzel J Dose, et al. 2001 Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis J Nucl Med 42 9 16 1:CAS:528:DC%2BD3MXhtF2nsLc%3D 11197987
15. R Bos JJ van Der Hoeven E van Der Wall, et al. 2002 Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography J Clin Oncol 20 379 387 1:CAS:528:DC%2BD38XovVKisQ%3D%3D 11786564 10.1200/JCO.20.2.379 (Pubitemid 34072519)
16. A Buck H Schirrmeister T Kuhn, et al. 2002 FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters Eur J Nucl Med Mol Imaging 29 1317 1323 1:CAS:528:DC%2BD38Xnt1Gnsr8%3D 12271413 10.1007/s00259-002-0880-8 (Pubitemid 44392212)
17. TF Cermik A Mavi S Basu, et al. 2008 Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer Eur J Nucl Med Mol Imaging 35 475 483 17957366 10.1007/s00259-007-0580-5 (Pubitemid 351661670)
18. N Avril S Bense SI Ziegler, et al. 1997 Breast imaging with fluorine-18-FDG PET: quantitative image analysis J Nucl Med 38 1186 1191 1:STN:280:DyaK2szpvFSitQ%3D%3D 9255146
19. JP Crowe LP Adler RR Shenk, et al. 1994 Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings Ann Surg Oncol 1 132 140 7834438 10.1007/BF02303557
20. T Inoue K Yutani T Taguchi, et al. 2004 Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-deoxy-2-fluoro-d-glucose- positron emission tomography J Cancer Res Clin Oncol 130 273 278 14986112 10.1007/s00432-003-0536-5 (Pubitemid 38680268)
21. 18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer Br J Surg 96 166 170 1:CAS:528:DC%2BD1MXjsVeqtbY%3D 19160365 10.1002/bjs.6459
22. S Basu W Chen J Tchou, et al. 2008 Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization Cancer 112 995 1000 1:CAS:528:DC%2BD1cXjs1eqsLo%3D 18098228 10.1002/cncr.23226 (Pubitemid 351304582)
23. LA Carey CM Perou CA Livasy, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast cancer Study J Am Med Assoc 295 2492 2502 1:CAS:528:DC%2BD28XlsV2rtLw%3D 10.1001/jama.295.21.2492 (Pubitemid 43854964)
24. KR Bauer M Brown RD Cress, et al. 2007 Descriptive analysis of oestrogen receptor-negative, progesterone receptor-negative and HER 2-negative invasive breast cancer, the so called triple negative phenotype: a population-based study from the California cancer Registry Cancer 109 1721 1728 17387718 10.1002/cncr.22618 (Pubitemid 46668532)
25. J Kim J Lee E Chang, et al. 2009 Selective sentinel node plus additional non-sentinel node biopsy based on an FDG PET/CT scan in early breast cancer patients: single institutional experience World J Surg 33 943 949 19259728 10.1007/s00268-009-9955-z